Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
77 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H1 2017 Summary According to the recently published report 'Caspase 3 - Pipeline Review, H1 2017'; Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Caspase-3 is a caspase protein encoded by the CASP3 gene. It interacts with caspase-8 and caspase-9. It cleaves and activates sterol regulatory element binding proteins (SREBPs) between the basic helix-loop-helix leucine zipper domain and the membrane attachment domain. It cleaves and activates caspase-6, -7 and -9. It is involved in the cleavage of huntingtin. It triggers cell adhesion in sympathetic neurons through RET cleavage The report 'Caspase 3 - Pipeline Review, H1 2017' outlays comprehensive information on the Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Genito Urinary System And Sex Hormones, Cardiovascular, Central Nervous System, Infectious Disease, Hematological Disorders, Immunology, Metabolic Disorders, Ophthalmology, Respiratory and Toxicology which include indications Prostate Cancer, Colorectal Cancer, Glomerulonephritis, Inflammatory Bowel Disease, Age Related Macular Degeneration, Alzheimer's Disease, Autoimmune Hepatitis, Bladder Cancer, Breast Cancer, Chemotherapy Induced Neutropenia, Diabetic Retinopathy, Febrile Neutropenia, Glioblastoma Multiforme (GBM), Hepatitis C, Hepatocellular Carcinoma, Huntington Disease, Liver Cirrhosis, Liver Failure (Hepatic Insufficiency), Liver Transplant Rejection, Metastatic Brain Tumor, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Myocardial Infarction, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Islet Transplant Rejection, Parkinson's Disease, Portal Hypertension, Primary Sclerosing Cholangitis, Pulmonary Fibrosis, Renal Failure, Solid Tumor, Spinal Cord Injury, Stroke, Traumatic Brain Injury, Urinary Tract Cancer and Zika Virus Infections. Scope - The report provides a snapshot of the global therapeutic landscape for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - The report reviews Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)targeted therapeutics and enlists all their major and minor projects - The report assesses Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Overview Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Companies Involved in Therapeutics Development Aptose Biosciences Inc BeyondSpring Pharmaceuticals Inc Conatus Pharmaceuticals Inc New World Laboratories Inc Pharmedartis GmbH Sanofi Shire Plc Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Drug Profiles 1G3-Cu - Drug Profile Product Description Mechanism Of Action R&D Progress BaxB-01 - Drug Profile Product Description Mechanism Of Action R&D Progress BaxG-03 - Drug Profile Product Description Mechanism Of Action R&D Progress BaxM-159 - Drug Profile Product Description Mechanism Of Action R&D Progress emricasan - Drug Profile Product Description Mechanism Of Action R&D Progress emricasan - Drug Profile Product Description Mechanism Of Action R&D Progress flavokawain A - Drug Profile Product Description Mechanism Of Action R&D Progress HaA-4 - Drug Profile Product Description Mechanism Of Action R&D Progress IDN-7314 - Drug Profile Product Description Mechanism Of Action R&D Progress NWL-53 - Drug Profile Product Description Mechanism Of Action R&D Progress plinabulin - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Activate CASP3 and CASP9 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Activate Caspases for Diabetic Retinopathy, Age Related Macular Degeneration and Solid Tumor - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Activate Caspase-3 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Activate Caspase 3 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Caspase 3 and Caspase 6 for Huntington's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Dormant Products Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Discontinued Products Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Product Development Milestones Featured News & Press Releases May 08, 2017: BeyondSpring Chief Medical Officer to Present at Three Prominent Industry Conferences in May 2017 Apr 25, 2017: BeyondSpring Enrolls First US Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia Prevention Mar 22, 2017: BeyondSpring Chief Medical Officer to Present on Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Prevention at BIO-Europe Spring 2017 Mar 20, 2017: BeyondSpring Lead Asset Plinabulin's Anti-Cancer Mechanism Accepted for Poster Presentation at the 2017 Keystone Symposia in British Columbia Mar 14, 2017: BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in Tokyo Feb 23, 2017: BeyondSpring Clinical Data for Lead Asset, Plinabulin, Accepted for Oral Presentation at IASLC's 2017 Targeted Therapies of the Treatment of Lung Cancer Feb 21, 2017: BeyondSprings Promising Clinical Data for Lead Asset on Non-Small Cell Lung Cancer Treatment Selected for Presentation at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium Jan 24, 2017: FDA Accepts BeyondSpring IND Application for Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia Jan 10, 2017: BeyondSpring to Present at Biotech Showcase 2017 During Annual JPMorgan Healthcare Conference on January 10 in San Francisco Dec 19, 2016: BeyondSpring Presents Encouraging Clinical Data for Lead Asset on Chemotherapy-Induced Neutropenia at 2016 ASH Annual Meeting Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis Nov 03, 2016: BeyondSpring Clinical Data on Neutropenia Mitigation with Plinabulin to be Presented at 2016 ASH Annual Meeting Oct 03, 2016: Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting Sep 27, 2016: BeyondSpring Announces First Patient Enrolled in Phase 1b/2 Investigator-Initiated Trial of Plinabulin plus Nivolumab for Non-Small Cell Lung Cancer Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Aptose Biosciences Inc, H1 2017 Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017 Pipeline by Conatus Pharmaceuticals Inc, H1 2017 Pipeline by New World Laboratories Inc, H1 2017 Pipeline by Pharmedartis GmbH, H1 2017 Pipeline by Sanofi, H1 2017 Pipeline by Shire Plc, H1 2017 Dormant Products, H1 2017 Dormant Products, H1 2017 (Contd..1), H1 2017 Dormant Products, H1 2017 (Contd..2), H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
